Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.

被引：0
|
作者：
Tripathi, Abhishek
Xie, Wanling
Sweeney, Christopher
Choudhury, Atish Dipankar
Pomerantz, Mark
Wei, Xiao X.
Taplin, Mary-Ellen
Choueiri, Toni K.
Lee, Gwo-Shu Mary
Kantoff, Philip W.
Harshman, Lauren Christine
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17027
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis
    Rajanala, Sai Harisha
    Plym, Anna
    Vaselkiv, Jane B.
    Ebot, Ericka M.
    Matsoukas, Konstantina
    Lin, Zhike
    Chakraborty, Goutam
    Markt, Sarah C.
    Penney, Kathryn L.
    Lee, Gwo-Shu M.
    Mucci, Lorelei A.
    Kantoff, Philip W.
    Stopsack, Konrad H.
    CARCINOGENESIS, 2024, 45 (1-2) : 35 - 44
  • [32] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
    Bianchini, D.
    Lorente, D.
    Rodriguez-Vida, A.
    Omlin, A.
    Pezaro, C.
    Ferraldeschi, R.
    Zivi, A.
    Attard, G.
    Chowdhury, S.
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 78 - 84
  • [33] IMPACT OF C-REACTIVE PROTEIN KINETICS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH DOCETAXEL
    Saito, K.
    Ito, M.
    Kijima, T.
    Numao, N.
    Koga, F.
    Masuda, H.
    Fujii, Y.
    Kawakami, S.
    Urakami, S.
    Yuasa, T.
    Yamamoto, S.
    Yonese, J.
    Fukui, I
    Kihara, K.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 336 - 337
  • [34] Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.
    Rescigno, Pasquale
    Lorente, David
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Sideris, Spyridon
    Zafeiriou, Zafeiris
    Smith, Alan David
    Mehra, Niven
    Grist, Emily
    Jayaram, Anuradha
    Kolinsky, Michael Paul
    Lopez, Raquel Perez
    Mateo, Joaquin
    Parker, Chris
    Dearnaley, David Paul
    Hall, Emma
    Tunariu, Nina
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [35] Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
    Joshua, Anthony M.
    Shore, Neal D.
    Saad, Fred
    Chi, Kim N.
    Olsson, Carl A.
    Emmenegger, Urban
    Scholz, Mark C.
    Berry, William R.
    Mukherjee, Som
    Winquist, Eric
    Haas, Naomi B.
    Hasabou, Nahla
    Dmuchowski, Carl
    Perabo, Frank
    Hirmand, Mohammad
    Foley, Margaret A.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Multiple Docetaxel (DOC) Re-challenges (ReC) in Castration-resistant Prostate Cancer (CRPC) Patients (pts) - Outcomes and Predictive Factors of Response
    Caffo, O.
    Caldara, A.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Veccia, A.
    Pappagallo, G.
    Galligioni, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S500 - S500
  • [37] Polymorphisms of ABCB1 and CYP1B1 in prostate cancer patients treated with docetaxel
    Chioni, A.
    Giovannetti, E.
    Pastina, I.
    Lastella, M.
    Mey, V.
    Cianci, C.
    Nannizzi, S.
    Orlandini, C.
    Cacio, E.
    Danesi, R.
    Del Tacca, M.
    Ricci, S.
    ANNALS OF ONCOLOGY, 2005, 16 : 81 - 82
  • [38] Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study)
    Veccia, Antonello
    Ortega, Cinzia
    di Lorenzo, Giuseppe
    La Russa, Francesca
    Burgio, Salvatore Luca
    Facchini, Gaetano
    Messina, Caterina
    Sacco, Cosimo
    Spizzo, Gilbert
    Aieta, Michele
    Lodde, Michele
    Mansueto, Giovanni
    Zucali, Paolo A.
    D'Angelo, Alessandro
    Iacovelli, Roberto
    Massari, Francesco
    Morelli, Franco
    Procopio, Giuseppe
    Ruatta, Fiorella
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients
    Sin-Chi Chew
    Onkar Singh
    Xiangai Chen
    Rathi Devi Ramasamy
    Tejal Kulkarni
    Edmund J. D. Lee
    Eng-Huat Tan
    Wan-Teck Lim
    Balram Chowbay
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1471 - 1478
  • [40] ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population
    Tounsi, Nejia
    Trabelsi, Imen
    Kerkeni, Emna
    Grissa, Mohamed Habib
    Fredj, Nizar
    Sekma, Adel
    Mzali, Malek
    Hellara, Ilhem
    Monastiri, Kamel
    Douki, Wahiba
    Nouira, Semir
    PHARMACOLOGY, 2017, 99 (5-6) : 250 - 258
12345